Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126429521 | 12642952 | 1 | I | 20160803 | 20160811 | 20160811 | EXP | CA-AMGEN-CANSP2016102398 | AMGEN | 64.00 | YR | A | F | Y | 0.00000 | 20160810 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126429521 | 12642952 | 1 | PS | ENBREL | ETANERCEPT | 1 | Unknown | UNK | U | 103795 | UNKNOWN FORMULATION | ||||||||
| 126429521 | 12642952 | 2 | SS | METHOTREXATE. | METHOTREXATE | 1 | Oral | 25 MG, QWK | 0 | 25 | MG | /wk | |||||||
| 126429521 | 12642952 | 3 | SS | METHOTREXATE. | METHOTREXATE | 1 | Oral | 15 MG, QWK | 0 | 15 | MG | /wk | |||||||
| 126429521 | 12642952 | 4 | SS | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Unknown | 20 MG, QD | 0 | 20 | MG | QD | |||||||
| 126429521 | 12642952 | 5 | SS | HUMIRA | ADALIMUMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 126429521 | 12642952 | 6 | SS | REMICADE | INFLIXIMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 126429521 | 12642952 | 7 | SS | KINERET | ANAKINRA | 1 | Unknown | UNK | 0 | ||||||||||
| 126429521 | 12642952 | 8 | SS | ORENCIA | ABATACEPT | 1 | Unknown | UNK | 0 | ||||||||||
| 126429521 | 12642952 | 9 | SS | ACTEMRA | TOCILIZUMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 126429521 | 12642952 | 10 | C | RITUXAN | RITUXIMAB | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126429521 | 12642952 | 1 | Rheumatoid arthritis |
| 126429521 | 12642952 | 2 | Rheumatoid arthritis |
| 126429521 | 12642952 | 4 | Product used for unknown indication |
| 126429521 | 12642952 | 5 | Product used for unknown indication |
| 126429521 | 12642952 | 6 | Product used for unknown indication |
| 126429521 | 12642952 | 7 | Product used for unknown indication |
| 126429521 | 12642952 | 8 | Product used for unknown indication |
| 126429521 | 12642952 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126429521 | 12642952 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126429521 | 12642952 | Activities of daily living impaired | |
| 126429521 | 12642952 | Drug effect decreased | |
| 126429521 | 12642952 | Dyspnoea | |
| 126429521 | 12642952 | Infection | |
| 126429521 | 12642952 | Liver function test increased | |
| 126429521 | 12642952 | Osteomyelitis | |
| 126429521 | 12642952 | Rheumatoid arthritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126429521 | 12642952 | 2 | 1999 | 0 | ||
| 126429521 | 12642952 | 3 | 2016 | 0 | ||
| 126429521 | 12642952 | 4 | 1999 | 1999 | 0 | |
| 126429521 | 12642952 | 5 | 2009 | 0 | ||
| 126429521 | 12642952 | 7 | 1999 | 0 | ||
| 126429521 | 12642952 | 8 | 2010 | 0 | ||
| 126429521 | 12642952 | 10 | 2011 | 0 |